TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3932049

Group type: EXPERIMENTAL
Intervention: Misoprostol 100 micrograms administered q.i.d. for up to four weeks
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 286
Study: 29660425

Group type: EXPERIMENTAL
Intervention: Certolizumab 400 mg every 2 weeks for 16 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Certolizumab 200 mg every 2 weeks for 16 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo every 2 weeks for 16 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etanercept 50 mg twice weekly for 12 weeks
Number of subjects: 0
Study: 27096428

Group type: EXPERIMENTAL
Intervention: Exercise-Glucose (EG)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Rest-Glucose (RG)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Exercise-Fructose (EF)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Rest-Fructose (RF)
Number of subjects: 4
Study: 24968000

Group type: EXPERIMENTAL
Intervention: 8 mg moxidectin
Number of subjects: 172

Group type: COMPARATOR
Intervention: ivermectin
Number of subjects: 172
Study: 21846661

Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (STS) with brief repeated behavioral intervention (BRBI)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo patch with brief repeated behavioral intervention (BRBI)
Number of subjects: 246
Study: 20671013

Group type: EXPERIMENTAL
Intervention: Calcium supplements (≥500 mg/day)
Number of subjects: 20172
Study: 18209721

Group type: EXPERIMENTAL
Intervention: DNAemia cutoff of 10,000 copies per ml whole blood
Number of subjects: 83

Group type: COMPARATOR
Intervention: Antigenemia positivity for initiation of preemptive therapy
Number of subjects: 83
Study: 16174075

Group type: EXPERIMENTAL
Intervention: Leukocytapheresis (LCAP)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Prednisolone (PSL)
Number of subjects: 29
Study: 12556541

Group type: EXPERIMENTAL
Intervention: Intensive treatment (multifactorial intervention targeting hyperglycemia, hypertension, dyslipidemia, and microalbuminuria, along with secondary prevention with aspirin)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 160
Study: 10644551

Group type: EXPERIMENTAL
Intervention: Glucose infusion at 6 mg x kg(‐1) x min(‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glucose infusion at 2 mg x kg(‐1) x min(‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glucose pulse induction (6 mg x kg(‐1) x min(‐1))
Number of subjects: 6
Study: 9008993

Group type: EXPERIMENTAL
Intervention: Low-tack chewing gum
Number of subjects: 50

Group type: COMPARATOR
Intervention: Regular-tack chewing gum
Number of subjects: 50
Study: 1653671

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (320 fmol/min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 14
Study: 6301262

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid for 4 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid for up to 8 weeks (after initial 4 weeks of placebo for unhealed patients)
Number of subjects: 71
Study: 31515680

Group type: EXPERIMENTAL
Intervention: Robotic Surgery (RS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Laparoscopic Surgery (LS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Laparoscopic Surgery (LS) to Robotic Surgery (RS) transfer effect
Number of subjects: 12
Study: 30866837

Group type: EXPERIMENTAL
Intervention: End-ischemic dual hypothermic oxygenated machine perfusion (DHOPE) for 2 hours after static cold storage (SCS) before implantation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional static cold storage (SCS) only.
Number of subjects: 0
Study: 27480499

Group type: EXPERIMENTAL
Intervention: Digital rectal examination (DRE) posterior surface area estimates
Number of subjects: 30500

Group type: EXPERIMENTAL
Intervention: Highest quintile of DRE posterior surface area
Number of subjects: 30500

Group type: EXPERIMENTAL
Intervention: DRE posterior surface area
Number of subjects: 30500
Study: 25370155

Group type: EXPERIMENTAL
Intervention: Probiotic treatment for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotic treatment
Number of subjects: 0
Study: 23288881

Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin (EZ/S) 10/20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doubling the run-in statin dose (to simvastatin 40 mg or atorvastatin 20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Switching to rosuvastatin 10 mg
Number of subjects: 0
Study: 22282731

Group type: EXPERIMENTAL
Intervention: All-ceramic (AC) restorations
Number of subjects: 36

Group type: COMPARATOR
Intervention: Metal-ceramic (MC) restorations
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All-ceramic (AC) crowns
Number of subjects: 36

Group type: COMPARATOR
Intervention: Metal-ceramic (MC) crowns
Number of subjects: 36
Study: 19421684

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 56

Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 56
Study: 16719649

Group type: EXPERIMENTAL
Intervention: Participants learning in a four-cue probabilistic environment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Learning analyses using rolling regression methods
Number of subjects: 0
Study: 14996137

Group type: EXPERIMENTAL
Intervention: Lamotrigine (long-term treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone (short-term treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Divalproex (short-term treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine (short-term treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venlafaxine (short-term treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lithium (long-term treatment)
Number of subjects: 0
Study: 12575569

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM) plus bronchial arterial infusion chemotherapy (BAIC)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Bronchial arterial infusion chemotherapy (BAIC) alone
Number of subjects: 76
Study: 9918434

Group type: EXPERIMENTAL
Intervention: Ribavirin plus IFNα
Number of subjects: 8

Group type: COMPARATOR
Intervention: IFNα alone
Number of subjects: 8
Study: 7848794

Group type: EXPERIMENTAL
Intervention: Semiautomatic blood pressure measuring device (UA‐751)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Standard mercury sphygmomanometer (physician readings)
Number of subjects: 156
Study: 3243913

Group type: EXPERIMENTAL
Intervention: Single 16 mg dose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.6 mg dose given hourly for 10 doses
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Initial dose of 4.8 mg, followed by 1.6 mg doses given every hour for seven additional doses
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dosing regimen 1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dosing regimen 2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dosing regimen 3
Number of subjects: 12
Study: 30626409

Group type: EXPERIMENTAL
Intervention: High-dose intramuscular scopolamine augmentation
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Low-dose intramuscular scopolamine augmentation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 66
Study: 27641483

Group type: EXPERIMENTAL
Intervention: Classroom-based air cleaner intervention
Number of subjects: 25
Study: 25796459

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.8 mg/kg, 16 cycles, IV every 3 weeks)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 329
Study: 22615325

Group type: EXPERIMENTAL
Intervention: Enhanced group (motivational interview with air quality data at visit 2)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (motivational interview with air quality data at visit 4)
Number of subjects: 59
Study: 21730077

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6-MP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19319941

Group type: EXPERIMENTAL
Intervention: Viral load
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Viral replication capacity
Number of subjects: 84

Group type: COMPARATOR
Intervention: Maternal humoral immune response
Number of subjects: 84
Study: 16964670

Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine (Engerix‐B SKB 20 microg) administered according to a 0, 1, 2 month regime.
Number of subjects: 29
Study: 14960293

Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz, 110% of motor threshold, 20 trains of 5 seconds duration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 0
Study: 11111813

Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Biseko (standardized serum protein solution)
Number of subjects: 24
Study: 9443168

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 884

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 884

Group type: COMPARATOR
Intervention: Betahistine
Number of subjects: 884
Study: 8329259

Group type: EXPERIMENTAL
Intervention: propofol 2.5 mg kg‐1
Number of subjects: 41

Group type: COMPARATOR
Intervention: thiopentone 5.0 mg kg‐1
Number of subjects: 41
Study: 3296355

Group type: EXPERIMENTAL
Intervention: Autologous BMT recipients (21 participants)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Allogeneic BMT recipients (56 participants)
Number of subjects: 96
Study: 30470646

Group type: EXPERIMENTAL
Intervention: Desmopressin ODT (25μg for women, 50μg for men)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Desmopressin ODT
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study: 29889060

Group type: EXPERIMENTAL
Intervention: Biofeedback postural training using Lumo Lift for three weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group wore a pedometer to track physical activity
Number of subjects: 31
Study: 27788457

Group type: EXPERIMENTAL
Intervention: Positive imagery manipulation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Neutral imagery manipulation
Number of subjects: 42
Study: 24622426

Group type: EXPERIMENTAL
Intervention: High pressure group
Number of subjects: 156

Group type: COMPARATOR
Intervention: Conventional pressure group
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 156
Study: 22318208

Group type: EXPERIMENTAL
Intervention: Peer-led intervention designed to improve hypertension knowledge, disease self-management behaviors, and health outcomes
Number of subjects: 219
Study: 20236406

Group type: EXPERIMENTAL
Intervention: Program 1
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Program 2
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Program 1 and Program 2
Number of subjects: 1292
Study: 18236300

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 32
Study: 15934450

Group type: EXPERIMENTAL
Intervention: Mand-elicited imitation (MEI)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Modeling with auditory bombardment (Mod-AB)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Both MEI and Mod-AB
Number of subjects: 29
Study: 14569237

Group type: EXPERIMENTAL
Intervention: 5-month endurance and strength training program
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nontrained subjects (control group)
Number of subjects: 15
Study: 10642369

Group type: EXPERIMENTAL
Intervention: Creatine (5 g Cr monohydrate + 20 g glucose) four times per day for 5 days
Number of subjects: 15
Study: 8697183

Group type: EXPERIMENTAL
Intervention: 100 mM HCl (pH 1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 5% NaCl (1711 mOsm/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bile
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Iso-osmolar sodium oleate
Number of subjects: 9

Group type: COMPARATOR
Intervention: 0.9% NaCl (Control)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 10 mL bolus of any solution
Number of subjects: 9
Study: 7971477

Group type: EXPERIMENTAL
Intervention: Tris (pH = 10.5) intravenous infusion followed by hyperventilation
Number of subjects: 39

Group type: COMPARATOR
Intervention: Chronic stable angina pectoris (control group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Healthy persons (control group)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Variant angina patients
Number of subjects: 39
Study: 3653415

Group type: EXPERIMENTAL
Intervention: Mifepristone 25 mg bid for 7 days
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg bid for 7 days
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Epostane 200 mg qid for 7 days
Number of subjects: 78
Study: 29717036

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 27402560

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (18-month duration, 86.3% adherence)
Number of subjects: 278
Study: 26159136

Group type: EXPERIMENTAL
Intervention: Motivational interviewing smoking cessation YOU‐TURN program
Number of subjects: 136

Group type: COMPARATOR
Intervention: General smoking cessation program
Number of subjects: 136
Study: 23953888

Group type: EXPERIMENTAL
Intervention: Isotretinoin-Lidose formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Innovator isotretinoin formulation
Number of subjects: 0
Study: 21156983

Group type: EXPERIMENTAL
Intervention: Mepivacaine 1.5%
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combination of 15 mL each of bupivacaine 0.5% and mepivacaine 1.5%
Number of subjects: 64
Study: 18949772

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 200
Study: 17718278

Group type: EXPERIMENTAL
Intervention: Live Lactobacillus acidophilus plus Bifidobacterium infantis (3 x 10(9) CFU) bid and ORS
Number of subjects: 71

Group type: COMPARATOR
Intervention: ORS only (Control group)
Number of subjects: 71
Study: 14738180

Group type: EXPERIMENTAL
Intervention: EEG biofeedback treatment
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo control condition
Number of subjects: 7
Study: 10768305

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) in dosages of 100‐1,600 mg/day
Number of subjects: 292
Study: 8534385

Group type: EXPERIMENTAL
Intervention: Electromyographic (EMG) motor Tinel's sign
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Clinical Tinel's sign
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined EMG and clinical Tinel's sign
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nerve conduction study (NCS) values from control nerves
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NCS/EMG abnormalities localized to the elbow
Number of subjects: 120
Study: 2199151

Group type: EXPERIMENTAL
Intervention: Keith Antireflux Valve (ARV) on the sump port of a double-lumen NG tube
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Keith Antireflux Valve (ARV)
Number of subjects: 0
Study: 749854

Group type: EXPERIMENTAL
Intervention: Carbenoxolone (CBX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbenoxolone plus antacids (CBX + AA)
Number of subjects: 0
Study: 31279962

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CTX) 50 mg daily (Arm A)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CTX) 50 mg daily with celecoxib 400 mg twice daily (Arm B)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (Arm A)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (Arm B)
Number of subjects: 52
Study: 28361199

Group type: EXPERIMENTAL
Intervention: #Tamojunto program (experimental group)
Number of subjects: 6658

Group type: COMPARATOR
Intervention: Control group (no school prevention program)
Number of subjects: 6658
Study: 26611120

Group type: EXPERIMENTAL
Intervention: Nutraceuticals (Armolipid Plus)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 100

Group type: COMPARATOR
Intervention: Combined therapy (Nutraceuticals + Ezetimibe)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nutraceuticals and Ezetimibe
Number of subjects: 100
Study: 24029536

Group type: EXPERIMENTAL
Intervention: Injectable heroin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injectable methadone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral methadone
Number of subjects: 0
Study: 22094449

Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing (DB)
Number of subjects: 29
Study: 19539099

Group type: EXPERIMENTAL
Intervention: ramipril 5 mg/d (low-dose group)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: ramipril 10 mg/d (high-dose group)
Number of subjects: 89

Group type: COMPARATOR
Intervention: ramipril (both formulations)
Number of subjects: 89
Study: 16432050

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 50 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 12.5 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg/day
Number of subjects: 30
Study: 14974268

Group type: EXPERIMENTAL
Intervention: Tegapore wound-contact material
Number of subjects: 0
Study: 11560454

Group type: EXPERIMENTAL
Intervention: Intravenous itraconazole followed by oral itraconazole solution
Number of subjects: 384

Group type: COMPARATOR
Intervention: Intravenous amphotericin B
Number of subjects: 384
Study: 9158080

Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/day
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg + MPA 2.5 mg/day
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: CEE 0.31 mg + MPA 2.5 mg/day
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg alone or with MPA
Number of subjects: 52
Study: 7850238

Group type: EXPERIMENTAL
Intervention: Modified method for nonchromatographic measurement of urinary lactose.
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (29 babies without lactose tolerance).
Number of subjects: 84
Study: 2901610

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Complete open drainage on admission
Number of subjects: 240
Study: 31634178

Group type: EXPERIMENTAL
Intervention: 7-week waiting period
Number of subjects: 265

Group type: COMPARATOR
Intervention: 11-week waiting period
Number of subjects: 265
Study: 29798601

Group type: EXPERIMENTAL
Intervention: New tail cap (Group A)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Original tail cap (Group B)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Comparison of fracture healing time
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Klemm function evaluation
Number of subjects: 34
Study: 25079560

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Low-vegetable meal
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: High-meat/low-rice meal
Number of subjects: 130

Group type: COMPARATOR
Intervention: Low-energy-density control meal
Number of subjects: 130
Study: 22706623

Group type: EXPERIMENTAL
Intervention: Tacrolimus (PR)
Number of subjects: 22
Study: 21704953

Group type: EXPERIMENTAL
Intervention: High-frequency electroacupuncture (120-Hz stimulation)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low-frequency electroacupuncture (2-Hz stimulation)
Number of subjects: 14
Study: 19169336

Group type: EXPERIMENTAL
Intervention: Selenium and aspirin (SAM)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Selenium (SM)
Number of subjects: 32
Study: 16871760

Group type: EXPERIMENTAL
Intervention: Keto amino acids
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 12934721

Group type: EXPERIMENTAL
Intervention: Problem-based learning
Number of subjects: 118

Group type: COMPARATOR
Intervention: Lecture-based learning
Number of subjects: 118
Study: 10746892

Group type: EXPERIMENTAL
Intervention: Standardized soy extract (SOYSELECT) 400 mg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg/day
Number of subjects: 100
Study: 8777352

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI); 127 metaphase II oocytes injected.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional insemination; 136 oocytes used.
Number of subjects: 13
Study: 1329135

Group type: EXPERIMENTAL
Intervention: Sealapex
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sankin apatite root sealer (Type II)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Roth's sealer
Number of subjects: 70

Group type: COMPARATOR
Intervention: Gutta‐percha without sealer
Number of subjects: 70
Study: 6369883

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide 2.5 mg
Number of subjects: 36
Study: 31335588

Group type: EXPERIMENTAL
Intervention: Daily PrEP
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Time-driven PrEP
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Event-driven PrEP
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Heavy alcohol use
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Greater number of sex partners
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Wisepill data
Number of subjects: 350